Vagivit

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vagivit

Quick Facts

Property Description
Active ingredient Sodium Ascorbate (a salt of Ascorbic Acid)
Form Vaginal tablet (pessary)
Pharmacological class Vaginal acidification agent, local pH regulator
General purpose Restoration and maintenance of the natural acidic vaginal environment
Origin Derived (a synthesized salt of a natural vitamin)

What is Vagivit and its Pharmaceutical Classification?

Vagivit is a monocomponent pharmaceutical preparation specifically formulated as a vaginal tablet, or pessary, for vaginal administration. This medicine is primarily classified as a vaginal acidification agent and a local pH regulator because its function is to change the local chemical balance. Locally applied vitamin C provides an effective and long-lasting pH-lowering effect and is a mechanism clinically recognized for its role in supporting the vaginal microecology.

The Composition and Purpose of Sodium Ascorbate

The single active ingredient in Vagivit is Sodium Ascorbate, the mineral salt form of Ascorbic Acid (Vitamin C), defining its composition. As a derived substance, Sodium Ascorbate is utilized to efficiently release the acidifying component after the tablet dissolves. The fundamental purpose of this compound is the restoration of normal vaginal pH to its naturally acidic range, typically pH 3.5-4.5. Vaginal ascorbic acid is used to improve abnormal vaginal pH and microflora, meaning the preparation is instrumental in re-establishing the conditions that promote the proliferation of beneficial Lactobacilli bacteria.

How Vagivit Differs from Other Vaginal Preparations

Vagivit provides a distinct non-antibiotic therapy, concentrating solely on microenvironmental correction, which differentiates it from broad-spectrum treatments. This approach is typically favored in scenarios where the goal is to reinforce natural defenses. The formulation uses an inert pharmaceutical base or vehicle designed as a sustained-release matrix, ensuring the acidifying agent exerts its pH-modulating effect over an extended contact time. This focused action makes the product a localized tool for maintaining the ecosystem's self-regulating capacity, specifically targeting adult women seeking a non-hormonal way to support vaginal flora balance.

What side effects are possible with Vagivit?

Possible Side Effects and Safety Information

The assessment of possible side effects for this vaginal tablet is based on clinical experience and post-market surveillance of localized ascorbic acid preparations. Due to the route of administration, the officially documented adverse reactions are primarily confined to the treatment site, classified under Genitourinary System Disorders and Administration Site Conditions in regulatory documents.

Documented Adverse Reactions

The most commonly reported adverse reactions are localized symptoms that reflect the product's acidifying action. These include a genital burning sensation and vaginal itching. Other documented reactions include increased vaginal discharge and localized pain or erythema (redness of the skin) at the administration site. Post-market data also rarely reports systemic effects such as insomnia (Psychiatric Conditions) or abdominal bloating (Gastrointestinal Disorders).

Safety Constraints and Considerations

The medicine is contraindicated in individuals with a known hypersensitivity to the active substance, Sodium Ascorbate, or any of the inactive ingredients. Caution is advised for patients with an existing Candida infection (yeast infection), as use may lead to an intensification of the condition.

Regulatory documentation related to the active substance includes constraints for specific populations. For instance, individuals with Glucose-6-phosphate dehydrogenase (G6PD) deficiency carry a documented risk of haemolytic anaemia when exposed to high systemic doses of ascorbic acid. Use with caution is also advised for women who are pregnant or breast-feeding and for patients concurrently using anticoagulant medications, where interference with their effectiveness has been reported.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Vagivit (Ascorbic Acid) is based on the documented systemic effects of the active ingredient at extremely high exposure levels, typically associated with massive oral overdosage.

Documented Clinical Manifestations

Symptoms officially documented for excessive systemic intake include gastrointestinal disturbances, such as temporary diarrhoea, nausea, vomiting, and abdominal discomfort. Additional manifestations may include headache and mild diuresis (increased urination). Regulatory documents also note that high concentrations of Ascorbic Acid may interfere with the results of certain clinical-chemical laboratory tests, including those for urinary glucose, creatinine, and uric acid.

Severe Outcomes and Required Actions

Regulatory authorities highlight the risk of severe or life-threatening complications following massive overdosage, particularly in susceptible individuals. These risks include the formation of renal oxalate calculi (kidney stones) and subsequent acute renal failure. Individuals with Glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of haemolytic anaemia.

Urgent medical attention is required: The official mandate is to consult a doctor or seek medical attention immediately if the recommended dosage is exceeded or if severe clinical signs, particularly those affecting renal function, are suspected. No specific antidote is known; therefore, the documented management procedure is limited to providing symptomatic and supportive treatment.

Therapeutic Uses of Vagivit

What Vagivit Treats: Main Uses and Benefits

This supportive therapy is primarily used to manage conditions presenting with systemic or localized discomfort, addressing conditions involving episodic or fluctuating manifestations such as Bacterial Vaginosis (BV). This supportive approach may assist with maintaining the natural acidic state. The core therapeutic aim is to support general well-being during symptomatic phases.

The medication is commonly used to help with symptom clusters related to physical discomfort, such as symptoms that interfere with daily functioning like odor and discharge. It is relevant for easing distress and is commonly used to support patients during the long-term management of recurrent BV episodes following initial acute treatment. This supportive effect contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

“This supportive treatment is relevant in clinical settings involving symptoms related to systemic imbalance, and may assist with maintaining functional stability.”


Quick Fact: Relief for Vaginal Discomfort Vagivit is relevant for easing symptoms in recurrent episodes of Bacterial Vaginosis, supporting the maintenance of a stable vaginal environment, which contributes to the reduction of symptomatic recurrence.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vagivit?

This section outlines the official population eligibility and non-eligibility rules for Vagivit, based strictly on government regulatory information.

Approved and Studied Population

Use of Vagivit is established for Adult Females between the ages of 18 and 65 years.

Absolute Contraindications The medicine must not be used in the following populations, as defined by official labeling:

  • Known Hypersensitivity: Individuals with a documented allergy or hypersensitivity to Ascorbic Acid (Sodium Ascorbate) or any other component of the vaginal tablet.
  • Vaginal Fungal Infection: Women with a confirmed or suspected vaginal yeast infection (such as candidiasis). Regulatory documents specify this restriction because the product's pH-lowering mechanism may promote the proliferation of yeast organisms.

Populations with Restricted or Conditional Use

Use in these groups is generally not established or requires specific medical assessment:

  • Pediatric and Geriatric Females: Use is not established in females under 18 years and those over 65 years due to insufficient clinical data.
  • Pregnancy and Lactation: Use during pregnancy or breastfeeding is classified as conditional use and requires assessment by a healthcare professional.
  • Concomitant Therapies: The use of Vagivit is restricted during the simultaneous administration of other vaginal products or therapies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Vagivit, derived strictly from government regulatory documentation for the active substance, Sodium Ascorbate, and its local route of administration.

Local Administration Restrictions and Timing

Vagivit is a local pH-modulating agent, and co-administration with other vaginal preparations requires mandatory administration separation. This restriction is necessary to prevent the active substance from chemically or physically interfering with the co-administered product’s intended efficacy.

Systemic Drug and Nutrient Interactions

Regulatory documents detail that the active substance, Ascorbate, has been reported to reduce the effectiveness of anticoagulants such as Warfarin. Furthermore, Ascorbic Acid has a documented interaction mechanism where it increases the oral absorption of nonheme iron from iron-containing products.

Formal Interaction Restrictions

A contraindicated combination exists when high-dose Ascorbic Acid is given with Deferoxamine in patients with established iron-overload conditions. This restriction is due to the risk of enhanced iron chelation leading to serious cardiac concerns.

Population-Specific Interaction Notes

The interaction profile includes specific population cautions. Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are identified as having a heightened risk of precipitating haemolytic anaemia when exposed to the active substance. Additionally, patients with renal insufficiency are noted to be at risk of hyperoxalataemia if high systemic exposure occurs.

Mechanism of Action

Physiochemical pH Regulation

The mechanism of action is one of localized physiochemical modulation of the vaginal environment's buffer system. The active component, Ascorbic Acid, acts as a proton donor ( H^+), directly and immediately reducing the local pH toward the physiological acidic range ( pH 3.5-4.5). This chemical action establishes the low- pH condition that precedes and enables subsequent biological effects.

Environmental Selective Pressure

The sustained low pH exerts a selective pressure on the local microflora. This acidic environment acts as a growth inhibitor for competing non-acidophilic microorganisms while simultaneously promoting the proliferation and adherence of acid-tolerant extitLactobacilli. This change in biological selectivity is the mechanism for establishing competitive microbial dominance.

Activation of the Lactic Acid Physiological Feedback Loop

The mechanism culminates in the activation of the host's natural physiological pathway. By promoting the rapid re-establishment of the extitLactobacilli population, the low pH facilitates the bacteria's resumption of metabolic function: converting epithelial glycogen into Lactic Acid. This production of endogenous Lactic Acid then supports the sustained maintenance of the acidic environment.

Dosage and Administration Information

How to Use Vagivit: Administration Guidelines

Vagivit (Ascorbic Acid) is administered solely as a vaginal tablet using the intravaginal route. This local application ensures the acidifying agent is delivered directly to the target area. The dosage, timing, and regimen follow established guidelines for this pharmaceutical class.

Administration Details

The table below outlines the specific usage parameters as described in product documentation.

Parameter Standard Guidelines
Route of Administration Intravaginal (local application only). The tablet is not for oral use and must not be swallowed.
Standard Unit Dose One vaginal tablet (typically 250 mg of Ascorbic Acid equivalent).
Frequency and Timing Once a day, preferably administered at bedtime to ensure the longest possible contact time.
Insertion Technique Insert the tablet deeply into the vagina, often recommended while in a lying position.
Special Use in Pregnancy If used during pregnancy, insertion is often recommended without an applicator (by finger insertion) to minimize risk.

Treatment Courses and Regimens

Vagivit is used in distinct, time-bound courses rather than continuously. For a standard treatment course, the regimen typically requires daily use for 6 consecutive days.

For long-term management or prophylaxis against recurrence, the medicine is often prescribed in a cyclic administration pattern. This usually involves repeating the 6-day course monthly, often starting immediately after menstruation has ended.

Missed Doses

If a dose is forgotten, it should be used as soon as the individual remembers, unless it is close to the next scheduled dose. In that case, the missed dose should be skipped, and the regular schedule resumed. The dosage must not be doubled to make up for a missed tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vagivit

Research into vaginal ascorbic acid (the active ingredient in Vagivit) focuses on its local impact on the vaginal microenvironment and how its use was studied for associations with changes in biological markers. The available studies contribute to understanding symptom patterns about how the substance is used in research exploring how symptoms change over time. Findings describe group patterns, not personal outcomes, and should not be confused with individual predictions.


Evidence for Use in Supporting Recurrent Bacterial Vaginosis (BV)

Vagivit was studied for its use as a supportive measure for adult women who experience conditions characterized by fluctuating or episodic manifestations such as recurrent Bacterial Vaginosis (BV). Researchers conducted Randomized Controlled Trials (RCTs) and systematic reviews to examine how this approach, typically used after a woman has completed initial antibiotic treatment, was studied for associations with patterns of change in the condition. These studies monitored patients with a history of BV over defined time intervals to assess how the frequency of new episodes evolved.

The clinical trials measured key outcomes related to systemic or functional imbalance, primarily focusing on the rate of BV recurrence (relapse) over periods up to six months. Studies reported how symptoms evolved in the observed populations, noting that measurements of BV recurrence rates were lower in the group receiving the substance compared to the placebo group in some trials.

Study Outcomes for Symptom Management

The research has also explored outcomes related to physical discomfort during symptomatic phases of BV. Studies tracked and reported how patients experienced changes related to common symptoms such as odor and unusual discharge using standardized scales. Findings describe patterns observed in which studies reported measurements of symptom resolution, particularly the patterns of symptom variability related to odor and discharge.


Evidence for Vaginal pH and Microflora Correction

The fundamental research for Vagivit was evaluated in studies that examined its local physical effect as an acidification agent. Clinical studies included adult women presenting with abnormal vaginal pH (a higher-than-normal reading). Research explored associations between its use and patterns related to Lactobacilli bacteria.

Studies consistently reported measurements indicating a reduction in vaginal pH following the application, and data show patterns related to a subsequent increase in Lactobacilli populations. Evidence is limited regarding the direct, long-term clinical implication of the biomarker change alone (pH normalization). While the chemical effect was observed in some studies, certainty remains low regarding associations between this biomarker change and the rate of recurrence.


Key Limitations and Areas of Uncertainty in the Research

The research highlights several areas where data quality varies across studies or where more evidence is needed. The primary limitation is that the treatment was studied for patterns of recurrence in some trials, but the evidence is mainly contextualized for its role as a maintenance therapy following initial treatment. Furthermore, while the evidence consistently describes the local pH-lowering effect, the findings were mixed regarding the overall certainty of preventing recurrence across all trials.

Frequently Asked Questions (FAQ)

Common questions about Vagivit (FAQ)

Q: Does Vagivit work right away, or does it take a few days?

The primary chemical effect of lowering the vaginal pH begins quickly after the first tablet is inserted, as the product is designed for continuous release over 24 hours. However, the full clinical and biological effects, such as the complete restoration of the natural microflora and symptom relief, may take longer to develop.


Q: Can Vagivit interact with common vitamins or supplements?

Official product information notes specific warnings about interactions with iron-containing products and anticoagulants like Warfarin. This is because a small amount of the active ingredient may be systemically absorbed. However, interactions with most general vitamins or dietary supplements are not typically detailed in the local product labeling.


Q: Does Vagivit have any known long-term side effects?

The product has been studied for use in long-term maintenance cycles lasting up to six months. The documented adverse reactions are mainly localized (such as burning or itching) and often appear at the beginning of the treatment cycle. Official product information does not detail long-term adverse events uniquely associated with this localized use.


Q: Are there different strengths or forms of Vagivit available?

According to official regulatory documents, the established formulation is the 250 mg Ascorbic Acid vaginal tablet. The use and studies of the medicine detail this specific unit dose. Other strengths or alternative topical forms, such as creams or gels, are not typically recognized in official product labeling for Vagivit.


Q: What is the success rate often reported in clinical trials for Vagivit?

Studies have examined the medicine's association with patterns of change in recurrent Bacterial Vaginosis (BV) following initial antibiotic treatment. Findings from one randomized trial indicated that the risk of BV recurrence was halved in the group receiving the substance, compared to the placebo group, over a six-month monitoring period.


Q: How long do the effects of Vagivit typically last after stopping treatment?

The product is designed to support the vaginal environment, which is assessed over time by monitoring the risk of recurrence. Studies showed a higher likelihood of no recurrence from the fifth month onwards when the cyclic maintenance regimen was followed. This suggests the benefit is achieved through sustained, repeated use rather than a singular, fixed duration of effect after one course.


Q: Does the scientific research on Vagivit show consistent results?

Research consistently confirms that the product achieves its primary physical goal: the local reduction of vaginal pH. However, official reviews of clinical trials indicate that the findings regarding the overall certainty of preventing recurrence of conditions like Bacterial Vaginosis were mixed across all studies examined.


Q: Is Vagivit only available by prescription?

Official product labeling does not always explicitly classify the medicine as prescription-only. However, due to certain conditional use requirements and safety constraints (like a known yeast infection), it is important that use is discussed with a healthcare professional or pharmacist to ensure its appropriateness.


Q: Are there any foods or drinks I should avoid while using Vagivit?

Official product information for the vaginal tablet does not list any specific restrictions or warnings concerning the consumption of food or drinks while the medicine is being used.


Q: Is it true that Vagivit can cause weight changes?

According to the official product labeling, weight change is not listed among the documented adverse reactions associated with the use of this vaginal tablet.


Q: Do the side effects of Vagivit usually go away on their own?

Localized side effects, such as mild burning or itching, are generally temporary in nature. Studies have reported that these reactions are typically mild and often resolve within 1–2 days without the need for additional countermeasure or treatment.


Q: Can Vagivit affect the result of a Pap smear or other lab tests?

The active ingredient, Ascorbic Acid, is known to have the potential to interfere with the results of certain laboratory tests, including occult blood tests and some blood sugar screenings. Official patient information indicates that individuals are typically instructed to inform their healthcare professional that they are using this product prior to undergoing laboratory testing.


Q: Do I need to see a doctor before starting Vagivit?

Regulatory documents specify that a medical assessment is necessary for women in conditional use categories, such as those who are pregnant or breastfeeding. Since the medicine is contraindicated in the presence of a known yeast infection, it is important that individuals consult a healthcare professional to confirm the appropriateness of starting the product.


Q: Is Vagivit recommended for women with a history of cancer?

Regulatory warnings state that the active substance, Ascorbic Acid, has been associated with potential interactions with certain types of chemotherapy and cancer treatments. For women with a history of cancer, the healthcare professional should be informed about the use of this product.


Q: Does alcohol consumption affect how Vagivit works?

Official product labeling for the vaginal tablet does not include specific warnings or restrictions concerning alcohol consumption while the medicine is being used.


Q: Does Vagivit cause any mood changes or headaches?

Official documentation of adverse reactions for the active substance has rarely included headaches and insomnia. It is important to note that mood changes are not listed among the documented reactions in the product's official information.


Q: Is it necessary to use Vagivit at the same time every day?

The administration schedule detailed in regulatory guidelines specifies once-a-day use, preferably at bedtime, to achieve the longest duration of contact. The official instructions for missed doses provide a procedure for resuming the regular schedule, indicating the focus is on daily use.


Q: Are there any specific activities to avoid after using Vagivit?

Official warnings generally advise against engaging in specific activities during the course of treatment. This typically includes avoiding sexual intercourse, douching, and the use of other vaginal products, unless a healthcare professional has given alternative instruction.


Q: Does Vagivit contain any ingredients derived from animals?

The composition of the vaginal tablet includes the active ingredient (Ascorbic Acid) and excipients (inactive ingredients). Official warnings indicate that some formulations of the tablet may contain small traces of bovine milk proteins as part of these excipients.


Q: Can Vagivit interact with any common pain relievers?

Regulatory documents note that high doses of the active ingredient (Ascorbic Acid) have a potential interaction with certain common pain relievers, such as NSAIDs and Acetaminophen. This may increase the risk of certain kidney problems, though the risk is considered lower due to the local administration of the vaginal tablet.


Q: Does Vagivit affect blood pressure?

According to the official product labeling, blood pressure changes are not listed among the documented adverse reactions associated with the use of this vaginal tablet.


Q: Can I use Vagivit if I am currently taking medication for high cholesterol?

Regulatory warnings state that the systemic absorption of Ascorbic Acid has been reported to potentially reduce the effectiveness of certain cholesterol medications, specifically statins and niacin. For patients taking medication for high cholesterol, the healthcare professional should be informed about the use of this product.

How should Vagivit be stored and disposed of?

Storage and Environmental Requirements

Official regulatory labeling for Vagivit (Sodium Ascorbate vaginal tablets) mandates specific conditions to ensure product quality. The medicine must be stored at controlled room temperature and generally not above 30 C. The tablets must be kept in the original container, tightly closed, and protected from light and moisture to prevent degradation of the active substance.

Stability and Child Safety

For certain types of packaging, such as multi-dose bottles, there is an official post-opening limit, requiring the product to be discarded 100 days after first opening. As with all medicines, it must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste. The medicine must not be released to the environment or thrown into household drains or watercourses, as documented in official regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vagivit found in:

A-Z Index: